Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Salvage Therapy in Relapsed or Refractory DLBCL
J Clin Oncol; ePub 2016 Dec 28; van Imhoff, et al
Ofatumumab or rituximab combined with cisplatin, cytarabine, and dexamethasone (DHAP) were similarly effective as salvage therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to a study involving 447 individuals.
Participants had CD20+ DLBCL and experienced first relapse or were refractory to first-line R-CHOP-like treatment. They were randomly assigned to 3 cycles of R-DHAP or O-DHAP, with the third cycle given only if there was response to the first 2. This was followed by high-dose therapy and ASCT. Investigators looked at survival rates. Among the results:
- Response rate/complete response rate for O-DHAP was 38%/15%; it was 42%/22% for R-DHAP.
- One-third of patients taking ofatumumab completed ASCT, vs 37% of those given rituximab.
- At 2 years, survival rates were similar in both groups; progression-free survival was ~25%; event free survival was ~17%, and overall survival was ~39.5%.
- Negative PET prior to ASCT predicted superior outcome.
van Imhoff G, McMillan A, Matasar M, et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: The ORCHARRD Study. [Published online ahead of print December 28, 2016]. J Clin Oncol. doi:10.1200/JCO.2016.69.0198.